NEW YORK , Aug. 6, 2024 /PRNewswire/ -- The global colorectal cancer therapeutics market size is estimated to grow by USD 2.00 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 4.5% during the forecast period. Increasing geriatric population is driving market growth, with a trend towards development of small molecule kinase inhibitors.
However, patent expiration of novel therapeutics poses a challenge. Key market players include Accord Healthcare Ltd., Amgen Inc.
, Amneal Pharmaceuticals Inc., Bayer AG, Biocon Ltd., Bristol Myers Squibb Co.
, CK Hutchison Holdings Ltd., Eli Lilly and Co., F.
Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Hetero Drugs Ltd.
, Hikma Pharmaceuticals Plc, Merck and Co. Inc., Ono Pharmaceutical Co.
Ltd., Otsuka Holdings Co. Ltd.
, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.
, and Viatris Inc.. Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report Market Driver The colorectal cancer therapeutics market is currently dominated by biologics, but their high development costs, complex processes, and associated side effects are limiting their adoption.
In response, pharmaceutical companies are focusing on creating safe, affordable, and easy-to-administer small molecule drugs. These drugs primarily target protein kinases, which catalyze phosphorylation and regulate cellular processes like division,.